Additionally, RNA-edited sites, including the specific site in SOCS2-AS1 at Chr12:935,429,429 (T/C) (n = 32), has been linked to survival probability in AML patients compared to non-edited sites (n = 119) [32]. The gene discussed is SOCS2; the disease is acute myeloid leukemia.